|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Changes in lymphocyte subpopulations in peripheral blood of healthy controls vs TSAb- Graves’ disease patients and healthy controls vs TSAb+ Graves’ disease patients** | | | | | |
|  |  |  |  |  |  |
|  | **% healthy controls** | **% TSAb- GD patients** | **p** | **% TSAb+ GD patients** | **p** |
| **CD3+ lymphocytes** | 72.5 (66.1-76.9) | 72.35 (63.35-77.5) | ns | 72.7 (64.95-75.5) | ns |
| **CD4+ lymphocytes** | 63.3 (59.5-68.9) | 65.7 (61.88-72.18) | ns | 67.4 (65.4-71.9) | ns |
| **CD4 naïve** | 31.35 (26.27-40.20) | 33.35 (28.45-40.43) | ns | 41.7 (31-46.93) | ns |
| **CD4 central memory** | 30.32 (24.48-33.26) | 27.55 (22.55-31.13) | ns | 27.85 (22.5-31.48) | ns |
| **CD4 early EM** | 21.28 (17.61-28.93) | 22.3 (17.23-27.55) | ns | 17.9 (14.83-25.58) | ns |
| **CD4 late EM** | 7.75 (4.85-10.39) | 5.6 (3.23-7.28) | ns | 5.35 (3.1-8.23) | ns |
| **CD4 TEMRA** | 0.76 (0.12-2.25) | 0.1 (0.03-1.83) | ns | 0.1 (0-0-43) | ns |
| **RTE** | 2.8 (2.1-4.3) | 3.5 (2.9-4.35) | ns | 3.45 (2.7-3.8) | ns |
| **Th17** | 4.5 (3.44-6.79) | 4.15 (3.15-5.3) | ns | 4.6 (3.2-5.3) | ns |
| **Tregs** | 4.85 (3.4-5.98) | 3.85 (2.25-5.08) | ns | 2.8 (2.1-3.8) | **p<0.05** |
| **Tregs HLA-DR+** | 1.95 (1.25-2.78) | 1.4 (0.8-2.05) | ns | 1.2 (0.8-1.6) | **p<0.05** |
| **CD8+ lymphocytes** | 28.8 (25.5-34.3) | 29.15 (23.98-32.45) | ns | 27.1 (24.2-31.7) | ns |
| **CD8 naïve** | 26.35 (18.82-41.6) | 29.3 (19.83-44.48) | ns | 39.2 (13.68-60.95) | ns |
| **CD8 central memory** | 8.59 (4.23-12.52) | 8.8 (6.13-11.73) | ns | 5.45 (4.15-9.2) | ns |
| **CD8 early EM** | 28.9 (21.3-31.93) | 27.25 (14.48-31.48) | ns | 16.2 (11.48-19.7) | **p<0.05** |
| **CD8 late EM** | 8.3 (5.6-10.99) | 6.3 (3.33-8.43) | ns | 5.15 (2.95-9.88) | ns |
| **CD8 TEMRA** | 15.72 (5.97-21.96) | 8.8 (4.05-37-05) | ns | 16.05 (2.08-28.9) | ns |
| **CD4+CD8+ (DPs)** | 0.8 (0.4-1.1) | 1.4 (0.88-2.7) | **p<0.01** | 1.3 (0.7-1.8) | **p<0.01** |
| **CD3+CD4+CD8+CD27+CCR7+CD45RA+** | 9.7 (1.5-16.2) | 8.95 (4.2-14.93) | ns | 9.95 (8.03-31.18) | ns |
| **CD3+CD4+CD8+CD27+CCR7+CD45RA-** | 21 (7.7-29.4) | 15.4 (9.13-24.33) | ns | 17.15 (13.53) | ns |
| **CD3+CD4+CD8+CD27+CCR7-CD45RA-** | 29.28 (14.7-40.8) | 39.35 (14.98-48.7) | ns | 32.25 (21.7-37.85) | ns |
| **CD3+CD4+CD8+CD27-CCR7-CD45RA-** | 6.2 (4.4-10.53) | 16.45 (11.63-35.9) | **p<0.01** | 16 (8.68-30.18) | **p<0.05** |
| **CD3+CD4+CD8+CD27-CCR7-CD45RA+** | 1.97 80.2-6.1) | 5.6 (1.53-11.93) | ns | 2.7 (0.75-6.83) | ns |
| **CD19+ cells** | 8.22 (6.05-10.78) | 9.25 (7.68-10.28) | ns | 9.2 (5.5-14.05) | ns |
| **Transitional B cells** | 8.52 (5.61-10.75) | 7.65 (4.45-9.9) | ns | 5.8 (2.5-11.1) | ns |
| **Naive** | 65.25 (50.43-76.35) | 66.8 (52.98-70.08) | ns | 62.3 (58.3-68.1) | ns |
| **Unswitched memory** | 8.4 (4.28-14.47) | 11.3 (8.15-18.98) | ns | 13.3 (9-19.4) | ns |
| **Switched memory** | 17.6 (10.3-27.13) | 18 (10.95-23.68) | ns | 17.5 (9.4-21.9) | ns |
| **Bregs** | 29.7 (21.9-36.33) | 17.9 (12.75-25.1) | ns | 25.2 (18.15-31.9) | ns |